|
1
|
Hasanzad M, Sarhangi N, Nikfar S, Ostad SN
and Aghaei Meybodi HR: A narrative review of current trends in
liraglutide: Insights into the unmet needs in management of type 2
diabetes and obesity. J Diabetes Metab Disord. 19:1863–1872.
2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
World Health Organization (WHO): Obesity
and Overweight, 2020. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
Accessed April 21, 2021.
|
|
3
|
Gadde KM, Martin CK, Berthoud HR and
Heymsfield SB: Obesity: Pathophysiology and management. J Am Coll
Cardiol. 71:69–84. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sims EA, Danforth E Jr, Horton ES, Bray
GA, Glennon JA and Salans LB: Endocrine and metabolic effects of
experimental obesity in man. Recent Prog Horm Res. 29:457–496.
1973.PubMed/NCBI View Article : Google Scholar
|
|
5
|
International Diabetes Federation: IDF
Diabetes Atlas-9th edition. http://www.diabetesatlas.org/(2019). Accessed April
21, 2021.
|
|
6
|
Zhang PY: Cardiovascular disease in
diabetes. Eur Rev Med Pharmacol Sci. 18:2205–2214. 2014.PubMed/NCBI
|
|
7
|
Cercato C and Fonseca FA: Cardiovascular
risk and obesity. Diabetol Metab Syndr. 11(74)2019.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Apovian CM, Okemah J and O'Neil PM: Body
weight considerations in the management of type 2 diabetes. Adv
Ther. 36:44–58. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
American Diabetes Association. 8. Obesity
management for the treatment of type 2 diabetes: Standards of
medical care in diabetes-2021. Diabetes Care. 44 (Suppl
1):S100–S110. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
American Diabetes Association. 9.
Pharmacologic approaches to glycemic treatment: Standards of
medical care in diabetes-2021. Diabetes Care. 44 (Suppl
1):S111–S124. 2021.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Herrmann C, Göke R, Richter G, Fehmann HC,
Arnold R and Göke B: Glucagon-like peptide-1 and glucose-dependent
insulin-releasing polypeptide plasma levels in response to
nutrients. Digestion. 56:117–126. 1995.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Müller TD, Finan B, Bloom SR, D'Alessio D,
Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF,
et al: Glucagon-like peptide 1 (GLP-1). Mol Metab. 30:72–130.
2019.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Holst JJ: The physiology of glucagon-like
peptide 1. Physiol Rev. 87:1409–1439. 2007.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Drucker DJ: Glucagon-like peptide-1 and
the islet beta-cell: Augmentation of cell proliferation and
inhibition of apoptosis. Endocrinology. 144:5145–5148.
2003.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lee YS and Jun HS: Anti-diabetic actions
of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism.
63:9–19. 2014.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Tang-Christensen M, Vrang N and Larsen PJ:
Glucagon-like peptide containing pathways in the regulation of
feeding behaviour. Int J Obes Relat Metab Disord. 25 (Suppl
5):S42–S47. 2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Rinaman L: Ascending projections from the
caudal visceral nucleus of the solitary tract to brain regions
involved in food intake and energy expenditure. Brain Res.
1350:18–34. 2010.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Chilton R, Wyatt J, Nandish S, Oliveros R
and Lujan M: Cardiovascular comorbidities of type 2 diabetes
mellitus: Defining the potential of glucagonlike peptide-1-based
therapies. Am J Med. 124 (Suppl):S35–S53. 2011.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Nikolaidis LA, Mankad S, Sokos GG, Miske
G, Shah A, Elahi D and Shannon RP: Effects of glucagon-like
peptide-1 in patients with acute myocardial infarction and left
ventricular dysfunction after successful reperfusion. Circulation.
109:962–965. 2004.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Meier JJ, Gethmann A, Götze O, Gallwitz B,
Holst JJ, Schmidt WE and Nauck MA: Glucagon-like peptide 1
abolishes the postprandial rise in triglyceride concentrations and
lowers levels of non-esterified fatty acids in humans.
Diabetologia. 49:452–458. 2006.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Gutzwiller JP, Tschopp S, Bock A, Zehnder
CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B
and Beglinger C: Glucagon-like peptide 1 induces natriuresis in
healthy subjects and in insulin-resistant obese men. J Clin
Endocrinol Metab. 89:3055–3061. 2004.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Nauck MA and Meier JJ: Management of
endocrine disease: Are all GLP-1 agonists equal in the treatment of
type 2 diabetes? Eur J Endocrinol. 181:R211–R234. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Nauck MA, Quast DR, Wefers J and Meier JJ:
GLP-1 receptor agonists in the treatment of type 2
diabetes-state-of-the-art. Mol Metab. 46(101102)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Iepsen EW, Torekov SS and Holst JJ:
Liraglutide for type 2 diabetes and obesity: A 2015 update. Expert
Rev Cardiovasc Ther. 13:753–767. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Pandey A, Chawla S and Guchhait P: Type-2
diabetes: Current understanding and future perspectives. IUBMB
Life. 67:506–513. 2015.PubMed/NCBI View
Article : Google Scholar
|
|
26
|
Paley CA and Johnson MI: Abdominal obesity
and metabolic syndrome: Exercise as medicine? BMC Sports Sci Med
Rehabil. 10(7)2018.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Siddiqui S: Obesity and diabetes:
Interrelationship. Adv Obes Weight Manag Control. 8:155–158.
2018.
|
|
28
|
Nicola P, Ardeleanu E, Gadau C, Dorobantu
M, Darabont R, Tilea I, Varga A, Folescu R, Zamfir AS, Boanca M, et
al: Evaluation of biochemical and clinical parametres of
hypertension with type 2 diabetes mellitus. Rev Chim. 69:2402–2406.
2018.
|
|
29
|
Nolen-Doerr E, Stockman MC and Rizo I:
Mechanism of glucagon-like peptide 1 improvements in type 2
diabetes mellitus and obesity. Curr Obes Rep. 8:284–291.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Hinnen D: Glucagon-like peptide 1 receptor
agonists for type 2 diabetes. Diabetes Spectr. 30:202–210.
2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sorli C, Harashima SI, Tsoukas GM, Unger
J, Karsbøl JD, Hansen T and Bain SC: Efficacy and safety of
once-weekly semaglutide monotherapy versus placebo in patients with
type 2 diabetes (SUSTAIN 1): A double-blind, randomised,
placebo-controlled, parallel-group, multinational, multicentre
phase 3a trial. Lancet Diabetes Endocrinol. 5:251–260.
2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Ahrén B, Masmiquel L, Kumar H, Sargin M,
Karsbøl JD, Jacobsen SH and Chow F: Efficacy and safety of
once-weekly semaglutide versus once-daily sitagliptin as an add-on
to metformin, thiazolidinediones, or both, in patients with type 2
diabetes (SUSTAIN 2): A 56-week, double-blind, phase 3a, randomised
trial. Lancet Diabetes Endocrinol. 5:341–354. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Ahmann AJ, Capehorn M, Charpentier G,
Dotta F, Henkel E, Lingvay I, Holst AG, Annett MP and Aroda VR:
Efficacy and safety of once-weekly semaglutide versus exenatide ER
in subjects with type 2 diabetes (SUSTAIN 3): A 56-week,
open-label, randomized clinical trial. Diabetes Care. 41:258–266.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Aroda VR, Bain SC, Cariou B, Piletič M,
Rose L, Axelsen M, Rowe E and DeVries JH: Efficacy and safety of
once-weekly semaglutide versus once-daily insulin glargine as
add-on to metformin (with or without sulfonylureas) in
insulin-naive patients with type 2 diabetes (SUSTAIN 4): A
randomised, open-label, parallel-group, multicentre, multinational,
phase 3a trial. Lancet Diabetes Endocrinol. 5:355–366.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Rodbard HW, Lingvay I, Reed J, de la Rosa
R, Rose L, Sugimoto D, Araki E, Chu PL, Wijayasinghe N and Norwood
P: Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN
5): A randomized, controlled trial. J Clin Endocrinol Metab.
103:2291–2301. 2018.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Pratley RE, Aroda VR, Lingvay I, Lüdemann
J, Andreassen C, Navarria A and Viljoen A: SUSTAIN 7 investigators.
Semaglutide versus dulaglutide once weekly in patients with type 2
diabetes (SUSTAIN 7): A randomised, open-label, phase 3b trial.
Lancet Diabetes Endocrinol. 6:275–286. 2018.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Lingvay I, Catarig AM, Frias JP, Kumar H,
Lausvig NL, le Roux CW, Thielke D, Viljoen A and McCrimmon RJ:
Efficacy and safety of once-weekly semaglutide versus daily
canagliflozin as add-on to metformin in patients with type 2
diabetes (SUSTAIN 8): A double-blind, phase 3b, randomised
controlled trial. Lancet Diabetes Endocrinol. 7:834–844.
2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Zinman B, Bhosekar V, Busch R, Holst I,
Ludvik B, Thielke D, Thrasher J, Woo V and Philis-Tsimikas A:
Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in
type 2 diabetes (SUSTAIN 9): A randomised, placebo-controlled
trial. Lancet Diabetes Endocrinol. 7:356–367. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Capehorn MS, Catarig AM, Furberg JK, Janez
A, Price HC, Tadayon S, Vergès B and Marre M: Efficacy and safety
of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1.2 mg
as add-on to 1-3 oral antidiabetic drugs in subjects with type 2
diabetes (SUSTAIN 10). Diabetes Metab. 46:100–109. 2020.PubMed/NCBI View Article : Google Scholar
|
|
40
|
McCrimmon RJ, Catarig AM, Frias JP,
Lausvig NL, le Roux CW, Thielke D and Lingvay I: Effects of
once-weekly semaglutide vs once-daily canagliflozin on body
composition in type 2 diabetes: A substudy of the SUSTAIN 8
randomised controlled clinical trial. Diabetologia. 63:473–485.
2020.PubMed/NCBI View Article : Google Scholar
|
|
41
|
O'Neil PM, Birkenfeld AL, McGowan B,
Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M
and Wilding JPH: Efficacy and safety of semaglutide compared with
liraglutide and placebo for weight loss in patients with obesity: A
randomised, double-blind, placebo and active controlled,
dose-ranging, phase 2 trial. Lancet. 392:637–649. 2018.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wilding JPH, Batterham RL, Calanna S,
Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran
MTD, Wadden TA, et al: Once-weekly semaglutide in adults with
overweight or obesity. N Engl J Med. 384:989–1002. 2021.PubMed/NCBI View Article : Google Scholar
|
|
43
|
U.S. Food and Drug Administration: FDA
Approves New Drug Treatment for Chronic Weight Management: First
Since 2014. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014.
Accessed June 25, 2021.
|
|
44
|
Davies M, Færch L, Jeppesen OK, Pakseresht
A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A,
Wadden TA, et al: Semaglutide 2·4 mg once a week in adults with
overweight or obesity, and type 2 diabetes (STEP 2): A randomised,
double-blind, double-dummy, placebo-controlled, phase 3 trial.
Lancet. 397:971–984. 2021.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wadden TA, Bailey TS, Billings LK, Davies
M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard
D, et al: Effect of subcutaneous semaglutide vs placebo as an
adjunct to intensive behavioral therapy on body weight in adults
with overweight or obesity: The STEP 3 randomized clinical trial.
JAMA. 325:1403–1413. 2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Rubino D, Abrahamsson N, Davies M, Hesse
D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J,
Rubio MA, et al: Effect of continued weekly subcutaneous
semaglutide vs placebo on weight loss maintenance in adults with
overweight or obesity: The STEP 4 randomized clinical trial. JAMA.
325:1414–1425. 2021.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Aroda VR, Rosenstock J, Terauchi Y,
Altuntas Y, Lalic NM, Morales Villegas EC, Jeppesen OK,
Christiansen E, Hertz CL and Haluzík M: PIONEER 1 Investigators.
PIONEER 1: Randomized clinical trial of the efficacy and safety of
oral semaglutide monotherapy in comparison with placebo in patients
with type 2 diabetes. Diabetes Care. 42:1724–1732. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Rodbard HW, Rosenstock J, Canani LH,
Deerochanawong C, Gumprecht J, Lindberg SØ, Lingvay I, Søndergaard
AL, Treppendahl MB and Montanya E: PIONEER 2 Investigators. Oral
semaglutide versus empagliflozin in patients with type 2 diabetes
uncontrolled on metformin: The PIONEER 2 trial. Diabetes Care.
42:2272–2281. 2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Pratley R, Amod A, Hoff ST, Kadowaki T,
Lingvay I, Nauck M, Pedersen KB, Saugstrup T and Meier JJ: PIONEER
4 investigators. Oral semaglutide versus subcutaneous liraglutide
and placebo in type 2 diabetes (PIONEER 4): A randomised,
double-blind, phase 3a trial. Lancet. 394:39–50. 2019.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Yabe D, Nakamura J, Kaneto H, Deenadayalan
S, Navarria A, Gislum M and Inagaki N: PIONEER 10 Investigators.
Safety and efficacy of oral semaglutide versus dulaglutide in
Japanese patients with type 2 diabetes (PIONEER 10): An open-label,
randomised, active-controlled, phase 3a trial. Lancet Diabetes
Endocrinol. 8:392–406. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Marso SP, Bain SC, Consoli A, Eliaschewitz
FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren
ML, et al: Semaglutide and cardiovascular outcomes in patients with
type 2 diabetes. N Engl J Med. 375:1834–1844. 2016.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Górriz JL, Soler MJ, Navarro-González JF,
García-Carro C, Puchades MJ, D'Marco L, Martínez Castelao A,
Fernández-Fernández B, Ortiz A, Górriz-Zambrano C, et al: GLP-1
receptor agonists and diabetic kidney disease: A call of attention
to nephrologists. J Clin Med. 9(947)2020.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Jódar E, Michelsen M, Polonsky W, Réa R,
Sandberg A, Vilsbøll T, Warren M, Harring S, Ziegler U and Bain S:
Semaglutide improves health-related quality of life versus placebo
when added to standard of care in patients with type 2 diabetes at
high cardiovascular risk (SUSTAIN 6). Diabetes Obes Metab.
22:1339–1347. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Husain M, Birkenfeld AL, Donsmark M,
Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I,
Mosenzon O, Pedersen SD, et al: Oral semaglutide and cardiovascular
outcomes in patients with type 2 diabetes. N Engl J Med.
381:841–851. 2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Hardy T, Oakley F, Anstee QM and Day CP:
Nonalcoholic fatty liver disease: Pathogenesis and disease
spectrum. Annu Rev Pathol. 11:451–496. 2016.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Non-alcoholic Fatty Liver Disease Study
Group. Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD,
Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, et al:
Epidemiological modifiers of non-alcoholic fatty liver disease:
Focus on high-risk groups. Dig Liver Dis. 47:997–1006.
2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Hazlehurst JM, Woods C, Marjot T, Cobbold
JF and Tomlinson JW: Non-alcoholic fatty liver disease and
diabetes. Metabolism. 65:1096–1108. 2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Mantovani A, Scorletti E, Mosca A, Alisi
A, Byrne CD and Targher G: Complications, morbidity and mortality
of nonalcoholic fatty liver disease. Metabolism.
111S(154170)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Lonardo A, Mantovani A, Lugari S and
Targher G: Epidemiology and pathophysiology of the association
between NAFLD and metabolically healthy or metabolically unhealthy
obesity. Ann Hepatol. 19:359–366. 2020.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Younossi ZM: Non-alcoholic fatty liver
disease-A global public health perspective. J Hepatol. 70:531–544.
2019.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Tarantino G, Citro V and Capone D:
Nonalcoholic fatty liver disease: A challenge from mechanisms to
therapy. J Clin Med. 9(15)2019.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Tarantino G and Balsano C:
Gastrointestinal peptides and nonalcoholic fatty liver disease.
Curr Opin Endocrinol Diabetes Obes. 27:11–15. 2020.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Lv X, Dong Y, Hu L, Lu F, Zhou C and Qin
S: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the
management of nonalcoholic fatty liver disease (NAFLD): A
systematic review. Endocrinol Diabetes Metab.
3(e00163)2020.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Mantovani A, Petracca G, Beatrice G,
Csermely A, Lonardo A and Targher G: Glucagon-like peptide-1
receptor agonists for treatment of nonalcoholic fatty liver disease
and nonalcoholic steatohepatitis: An updated meta-analysis of
randomized controlled trials. Metabolites. 11(73)2021.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Newsome PN, Buchholtz K, Cusi K, Linder M,
Okanoue T, Ratziu V, Sanyal AJ, Sejling AS and Harrison SA:
NN9931-4296 Investigators. A placebo-controlled trial of
subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J
Med. 384:1113–1124. 2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
European Medicines Agency: Ozempic:
summary of product characteristics; 2018. https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf.
Accessed April 24, 2021.
|
|
67
|
Gomez-Peralta F and Abreu C: Profile of
semaglutide in the management of type 2 diabetes: Design,
development, and place in therapy. Drug Des Devel Ther. 13:731–738.
2019.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Trujillo JM, Nuffer W and Ellis SL: GLP-1
receptor agonists: A review of head-to-head clinical studies. Ther
Adv Endocrinol Metab. 6:19–28. 2015.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Trujillo JM, Nuffer W and Smith BA: GLP-1
receptor agonists: An updated review of head-to-head clinical
studies. Ther Adv Endocrinol Metab.
12(2042018821997320)2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Shi FH, Li H, Cui M, Zhang ZL, Gu ZC and
Liu XY: Efficacy and safety of once-weekly semaglutide for the
treatment of type 2 diabetes: Protocol for a systematic review and
meta-analysis. Medicine (Baltimore). 97(e0420)2018.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Røder ME: Clinical potential of treatment
with semaglutide in type 2 diabetes patients. Drugs Context.
8(212585)2019.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Bjerre Knudsen L, Madsen LW, Andersen S,
Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL,
Hegelund AC, Jacobsen H, et al: Glucagon-like Peptide-1 receptor
agonists activate rodent thyroid C-cells causing calcitonin release
and C-cell proliferation. Endocrinology. 151:1473–1486.
2010.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Prasad-Reddy L and Isaacs D: A clinical
review of GLP-1 receptor agonists: Efficacy and safety in diabetes
and beyond. Drugs Context. 4(212283)2015.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Sfairopoulos D, Liatis S, Tigas S and
Liberopoulos E: Clinical pharmacology of glucagon-like peptide-1
receptor agonists. Hormones. 17:333–350. 2018.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Lando HM, Alattar M and Dua AP: Elevated
amylase and lipase levels in patients using glucagonlike peptide-1
receptor agonists or dipeptidyl-peptidase-4 inhibitors in the
outpatient setting. Endocr Pract. 18:472–477. 2012.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Abd El Aziz M, Cahyadi O, Meier JJ,
Schmidt WE and Nauck MA: Incretin-based glucose-lowering
medications and the risk of acute pancreatitis and malignancies: A
meta-analysis based on cardiovascular outcomes trials. Diabetes
Obes Metab. 22:699–704. 2020.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Diabetes Control and Complications Trial
Research Group. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford
O, Davis M, Rand L and Siebert C: The effect of intensive treatment
of diabetes on the development and progression of long-term
complications in insulin-dependent diabetes mellitus. N Engl J Med.
329:977–986. 1993.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Gorman DM, le Roux CW and Docherty NG: The
effect of bariatric surgery on diabetic retinopathy: Good, bad, or
both? Diabetes Metab J. 40:354–364. 2016.PubMed/NCBI View Article : Google Scholar
|
|
79
|
American Diabetes Association. 14.
management of diabetes in pregnancy: Standards of medical care in
diabetes-2021. Diabetes Care. 44 (Suppl 1):S200–S210.
2021.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Kelly AS, Auerbach P, Barrientos-Perez M,
Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N and Arslanian
S: NN8022-4180 Trial Investigators. A Randomized, controlled trial
of liraglutide for adolescents with obesity. N Engl J Med.
382:2117–2128. 2020.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Enebo LB, Berthelsen KK, Kankam M, Lund
MT, Rubino DM, Satylganova A and Lau DCW: Safety, tolerability,
pharmacokinetics, and pharmacodynamics of concomitant
administration of multiple doses of cagrilintide with semaglutide
2·4 mg for weight management: A randomised, controlled, phase 1b
trial. Lancet. 397:1736–1748. 2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Nauck MA and Quast DR: Cardiovascular
safety and benefits of semaglutide in patients with type 2
diabetes: Findings from SUSTAIN 6 and PIONEER 6. Front Endocrinol
(Lausanne). 12(645566)2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
ClinicalTrials.gov NCT03914326: A heart disease study
of semaglutide in patients with type 2 diabetes (SOUL). https://clinicaltrials.gov/ct2/show/NCT03914326.
Accessed July 10, 2021.
|
